Evidence map›Paper›PMID 21329845›Full record

ArticleJournal of the American College of Cardiology2011

Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction.

Mario Kasner, Dirk Westermann, Begoña Lopez, Regina Gaub, Felicitas Escher, Uwe Kühl, Heinz-Peter Schultheiss, Carsten Tschöpe

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04739215 (Effects of Sodium-Glucose Cotransporter 2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With Heart Failure With Preserved Ejection Fraction), which is not on this map. Cited by 150 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04739215 phase4unknown statusstarted 2021, after this paper: background citation

Effects of Sodium-Glucose Cotransporter 2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With Heart Failure With Preserved Ejection Fraction

Ran2021Enrolled62Registered outcomes10Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Heart Failure With Preserved Ejection FractionArmsDapagliflozin 10 MG [Farxiga], Placebo
PMID 23743396PMID 26378978PMID 28402411other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 1 synthesis or guideline pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Serum amyloid A in HFpEF and cardiometabolic diseases.Basic research in cardiology · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Cardiohepatic Axis in Cirrhosis.JACC. Basic to translational science · 2025
    Review
  17. Review
  18. Article
  19. Review
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mario KasnerDepartment of Cardiology and Pneumology, Campus Benjamin Franklin, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Dirk Westermann
Begoña Lopez
Regina Gaub
Felicitas Escher
Uwe Kühl
Heinz-Peter Schultheiss
Carsten Tschöpe
Charité - Universitätsmedizin Berlin · DEBerlin-Brandenburger Centrum für Regenerative Therapien · DEUniversidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe attempted to correlate echocardiographic analysis of diastolic function with changes of myocardial collagen in middle-aged patients with heart failure (HF) despite normal ejection fraction (EF).

backgroundIncreased collagen deposition may contribute to the deterioration of the left ventricular compliance and diastolic dysfunction in HF.

methodsWe investigated 41 patients (median age 50 years [interquartile range: 41 to 57 years]) with normal EF (median 62% [interquartile range: 56% to 70%]) whose endomyocardial biopsies were taken previously. Assessment of diastolic function was performed by mitral-flow and tissue Doppler measurements. Sirius red and immunohistologic staining was performed to determine collagen volume fraction (CVF) and cross-linking, collagen types I and III expression, and lysyl-oxidase (LOX) expression. Expression of collagen messenger ribonucleic acid was determined by real-time polymerase chain reaction.

resultsTwenty-six patients with HFNEF with diastolic dysfunction showed a significant increase in total collagen and collagen I expression compared with that of 15 controls. This was accompanied with enhanced collagen cross-linking and LOX overexpression in HFNEF. Among all flow Doppler, only deceleration time of E was associated with CVF (R = 0.43), whereas tissue Doppler parameters correlated with CVF, collagen I at the protein and mRNA levels (E' [R = -0.58, -0.60, -0.45]; E'/A' [R = -0.32, -0.36, -0.31]), and left ventricular filling index (E/E' [R = 0.72, 0.68, 0.63]), respectively. No correlation with collagen III was found. The degree of collagen cross-linking and LOX expression was related to E' (R = -0.55 and -0.60) and E/E' (R = 0.72 and 0.71), respectively, but not to flow Doppler. Collagen overexpression correlated with reduced exercise capacity.

conclusionsPatients with HFNEF showed increased content of myocardial collagen type I, enhanced collagen cross-linking, and LOX expression, which were associated with impaired diastolic tissue Doppler parameters.

Indexed as

AgedBiopsy, NeedleCase-Control StudiesCollagenDisease ProgressionEchocardiography, DopplerElasticity Imaging TechniquesFemaleHeart Failure, DiastolicHumansImmunohistochemistryMaleMiddle AgedMyocardiumPrognosisReference ValuesCollagen

Identifiers

PMID21329845
OpenAlexW2088776044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.